New Horizons in Unresectable Stage III NSCLC: A Case-based Exploration of Evolving Data and the Emergence of Immunotherapy
Join our Expert Faculty, Drs. Joel W. Neal, MD, PhD and Victoria Sherry, DNP, CRNP, AOCNP as they discuss treatment principles across the continuum of care in unresectable, stage III NSCLC. During their presentations and discussion, they will examine the established treatment landscape for unresectable, stage III NSCLC as well as the emerging role of immunotherapy, and practical clinical considerations for anticipating, mitigating, and managing immune-related adverse events.
Academic and community medical oncologists, radiation oncologists, thoracic surgeons, nurse practitioners, physician assistants, pharmacists, and oncology nurses.
- Review the prevalence and pathophysiology of unresectable stage III non–small cell lung cancer (NSCLC) and identify disease-specific clinical features relevant for chemoradiation therapy (CRT) and immuno-oncology (IO) decision making.
- Examine the current landscape of approved therapeutics in unresectable stage III NSCLC, emphasizing how the historical paucity of effective treatment options and resultant deficits in real-world patient outcomes have galvanized the need for novel approaches.
- Evaluate completed, ongoing, and planned clinical trial data for IO therapies in patients with unresectable stage III NSCLC, highlighting currently-approved IO regimens and emerging data across the treatment continuum.
- Recognize the presentation and anticipated time-course of immune-related adverse events (irAEs) and discuss evidence-based strategies for mitigation and management.
- Design individualized, evidence-supported treatment plans for patients with unresectable stage III NSCLC, with a particular focus on IO therapies following concurrent or sequential CRT.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from AstraZeneca.
5 min Welcome and Introductions
10 min Setting the Stage in Stage III: Prevalence, Pathophysiology, and Treatment Principles in Unresectable Disease
20 min Novel Approaches, Novel Outcomes: Renewing the Unresectable Stage III NSCLC Management Calculus with IO
15 min Multidisciplinary Momentum: Practical Principles for Implementing IO Regimens and Managing irAEs
10 min Conversations with the Experts/Audience Q&A
Joel W. Neal, MD, PhD (Activity Chair)
Associate Professor of Medicine, Division of Oncology
Medical Director for the Cancer Clinical Trials Office
Medical Director of Informatics
Stanford Cancer Center
Victoria Sherry, DNP, CRNP, AOCNP
Oncology Nurse Practitioner for Thoracic Malignancies
Abramson Cancer Center
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Evan Bryson, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Joel W. Neal, MD, PhD–has disclosed that he receives research support from Adaptimmune, AbbVie, Boehringer Ingelheim, Exelixis, Genentech/Roche, GSK, Janssen, Merck, Nektar Therapeutics, Novartis, and Takeda Pharmaceuticals. He is an advisor or consultant to Amgen, AstraZeneca, Blueprint Pharmaceuticals, Calithera Biosciences, D2G Oncology, Eli Lilly and Company, Exelixis, Genentech/Roche, Iovance Biotherapeutics, Jounce Therapeutics, Mirati Therapeutics, Natera, Regeneron Pharmaceuticals, Sanofi/Regeneron, Surface Oncology, Takeda Pharmaceuticals, and Turning Point Therapeutics. He also receives other financial or material support in the form of honoraria from Biomedical Learning Institute CME, Clinical Care Options CME, CME Matters, HMP Education, MJH Life Sciences CME, MLI Peerview CME, Medical Educator Consortium, Medscape CME, Prime Oncology CME, Projects in Knowledge CME, Research to Practice CME, and Rockpointe CME.
Victoria Sherry, DNP, CRNP, AOCNP–has disclosed that she is an advisor or consultant to AstraZeneca.
Katherine Lee, PharmD, MPH—has no relevant financial relationships to disclose in relation to the content of this activity.
Adam J. Schoenfeld, MD–has disclosed that he is an advisor or consultant to Bristol Myers Squibb, Enara Bio, Heat Biologics, Iovance Biotherapeutics, Johnson & Johnson, KSQ therapeutics, Lyell Immunopharma, Merck, and Perceptive Advisors. He also receives research funding from Achilles Therapeutics, Amgen, Bristol Myers Squibb, GlaxoSmithKlein, Harpoon Therapeutics, Iovance Biotherapeutics, Merck, and PACT Pharma, Inc.
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-22-016-H01-P).
This activity is designated for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation